Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. - Wikidata - awgldk - TriplyDB

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

http://www.wikidata.org/entity/Q40192837

about

Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity How to Improve Therapeutic Ratio in Radiotherapy of HCC Tissue- and Serum-Associated Biomarkers of Hepatocellular Carcinoma Modulation of Autophagy by Sorafenib: Effects on Treatment Response Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances New perspectives in glioblastoma antiangiogenic therapy Mechanisms of ferroptosis Sorafenib-induced Scrotal Eczema Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment Mouse models of liver cancer: Progress and recommendations Current and future treatments for hepatocellular carcinoma Current systemic treatment of hepatocellular carcinoma: A review of the literature Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma Understanding the role of PIN1 in hepatocellular carcinoma Case analysis of complete remission of advanced hepatocellular carcinoma achieved with sorafenib Model-guided therapy for hepatocellular carcinoma: a role for information technology in predictive, preventive and personalized medicine Novel small molecule Raf kinase inhibitors for targeted cancer therapeutics Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors Evidence of distinct tumour-propagating cell populations with different properties in primary human hepatocellular carcinoma (3)D [corrected] quantification of tumor vasculature in lymphoma xenografts in NOD/SCID mice allows to detect differences among vascular-targeted therapies Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel Comprehensive evaluation of the anti-angiogenic and anti-neoplastic effects of Endostar on liver cancer through optical molecular imaging The study of a novel sorafenib derivative HLC-080 as an antitumor agent Distinct behaviour of sorafenib in experimental cachexia-inducing tumours: the role of STAT3 Ligand-target prediction by structural network biology using nAnnoLyze Small Molecule APY606 Displays Extensive Antitumor Activity in Pancreatic Cancer via Impairing Ras-MAPK Signaling ERK2 mediates inner hair cell survival and decreases susceptibility to noise-induced hearing loss Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.Extra-abdominal desmoid tumours: a review of the literature.Physical supports from liver cancer cells are essential for differentiation and remodeling of endothelial cells in a HepG2-HUVEC co-culture model.Integrated analysis of mutation data from various sources identifies key genes and signaling pathways in hepatocellular carcinoma.Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma.Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy.Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib.Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)?Cancer genomics identifies regulatory gene networks associated with the transition from dysplasia to advanced lung adenocarcinomas induced by c-Raf-1.The acute transcriptomic and proteomic response of HC-04 hepatoma cells to hepatocyte growth factor and its implications for Plasmodium falciparum sporozoite invasion.

P2860

Q24619987-B5190A37-DCFD-4EFB-8ACB-C4316A3DDB93 Q24620203-A17CDC66-984E-4ADC-A3B9-0602F4BCF740 Q26738862-762BAB58-7CFC-4BF9-8B13-33815D1AEE2B Q26743361-337C6DA9-0712-4708-A24E-2EF7CFC52974 Q26745320-E34780CD-9CF1-4192-BDD0-09D47FC41761 Q26745338-1D2B2883-AA38-4E56-9BE6-AB0FF2091FF5 Q26746028-1AFAA893-7495-4F68-8CD7-10F4152BA567 Q26751418-93003B57-DBE5-4A52-8C2D-03CC210ABB8B Q26770144-E2864CCE-9139-46AC-892B-C98C4918EDF5 Q26774623-B6446BBC-BC52-4BC8-BC52-29DC3DC48E82 Q26799788-E876F4A8-C3E8-49DF-887B-8DB19106FE6F Q26801211-4431C159-7CCE-4BF7-8507-C47EEF197B01 Q27026036-30E4AB54-3B5E-4844-BD2C-993DA330A9DA Q27853202-A73A2DC1-176B-4A4F-B9A6-1FDC89B84566 Q28073477-A1B64B63-AD70-4971-8542-196B97216C2F Q28083400-E9A838A4-800F-4A7B-9C3B-C8BEE39192A5 Q28087569-5017FE9D-C9F4-4A26-BE54-DA6E4235EA7A Q28265862-0FBF34CF-5364-4D32-8282-0E59FFBBB816 Q28478344-C9B9655C-BB99-4A2F-A5E2-272AF78F6256 Q28478709-6E0D97B0-3573-4F6B-9460-40AEDAD3B55E Q28488869-90890B8A-83CD-4BCC-86AC-B869B5CE0EAD Q28535159-D3E9627C-8B1F-4165-A4DA-532C062E69E3 Q28538538-CCAF1C86-055D-40B1-9BB1-4033F9801319 Q28540521-BC32A065-435E-4830-A125-4DA9F810D4A2 Q28542391-0CBDCD4F-9DB3-434F-9123-633460A37F79 Q28545126-926AE1E0-6FE2-425E-87C5-5AC2832DD543 Q28552433-CAF06F5E-CF4F-42BE-A37D-73C70BC663C6 Q30398327-36A9D0C5-D214-4B8D-8C8A-386B8319E769 Q30429122-4DEB37CD-5746-458C-8B83-E510640B9C6E Q30463805-5CF95286-285D-4AC3-9EDA-55EEBDA984A1 Q30653607-95C57A8F-2D6F-4091-A90F-E36700000E17 Q30834745-527CABEE-FAD6-475A-9F8C-E9B497D7701B Q33404877-7FC536F9-D351-4509-B59D-6489E6D6D921 Q33410974-268B2837-7580-4032-A893-5A43344C0EDE Q33414998-85B8A192-57C1-4165-A80A-F0C7CB88B615 Q33475230-8FFF8B67-4641-4AAA-9C49-F97FB1AC525D Q33495790-C280FA33-2B91-449F-AFA6-73559649F516 Q33496309-1CC8794A-0786-4B9B-8B8F-F6D816B2FF83 Q33509293-D310B9B5-24DC-4EF3-AF28-4498CF6F7774 Q33583133-0527D862-40FD-4AA2-8C02-D76FA9FCD6D6

P2860

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

http://www.wikidata.org/entity/Q40192837

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Sorafenib blocks the RAF/MEK/E ...... lar carcinoma model PLC/PRF/5.

@en

type

label

Sorafenib blocks the RAF/MEK/E ...... lar carcinoma model PLC/PRF/5.

@en

prefLabel

Sorafenib blocks the RAF/MEK/E ...... lar carcinoma model PLC/PRF/5.

@en

P1433

Q40192837-DBB6FF7F-7F4C-40CE-84AD-02650613A8BD

P1476

Q40192837-45835FD7-21A5-4FA9-8CCC-2AB77205252D

P2093

Q40192837-17A46B56-EF37-41DB-9C9A-BAC16C198FDD

Q40192837-389932CA-F75D-49CE-AA0F-F18C29001436

Q40192837-4B710A78-3713-4E50-A957-639F2A3994BB

Q40192837-6A423B3D-E26D-419C-BE97-AE9E78A7875C

Q40192837-8E43C4CB-9061-40A5-A002-A8C5ADA4B562

Q40192837-B61F50A2-AE24-45C5-8372-48E3D5EBEA51

Q40192837-D6F1C22B-0423-44FA-BF1F-C73B47EE35D0

Q40192837-E3714A90-6B8D-4614-8A9E-AB5DDE52431C

Q40192837-ED28AE6E-94CD-49ED-A25E-910A83A0427F

P304

Q40192837-49A69B00-AC1B-4C58-B213-5129120C98FF

P31

Q40192837-81EA7AA6-1B2E-4899-B0B2-CD8E71C9BC2E

P356

Q40192837-BD37D695-8308-4B93-8D67-3353277CB4BA

P407

Q40192837-49291599-5660-4ED6-877A-8A149B2A6C19

P433

Q40192837-1CAAC68A-F58F-41FD-A039-7C86273FA5A2

P478

Q40192837-69FDD2A0-5B9C-4917-82D5-9A86757FD112

P577

Q40192837-5BEE0497-9FCE-4504-AFA9-C6E7338D9A44

P698

Q40192837-E15A940B-D924-4DF5-AAAF-A87A3CCD3FB1

P356

0008-5472.CAN-06-1377

P1433

Cancer Research

P1476

Sorafenib blocks the RAF/MEK/E ...... lar carcinoma model PLC/PRF/5.

@en

P2093

Angela McNabola

http://www.w3.org/2001/XMLSchema#string

Charles Chen

http://www.w3.org/2001/XMLSchema#string

Christopher Carter

http://www.w3.org/2001/XMLSchema#string

Dean Wilkie

http://www.w3.org/2001/XMLSchema#string

Li Liu

http://www.w3.org/2001/XMLSchema#string

Mark Lynch

http://www.w3.org/2001/XMLSchema#string

Scott Wilhelm

http://www.w3.org/2001/XMLSchema#string

Xiaomei Zhang

http://www.w3.org/2001/XMLSchema#string

Yichen Cao

http://www.w3.org/2001/XMLSchema#string

P304

11851-11858

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-06-1377

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P577

2006-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17178882

http://www.w3.org/2001/XMLSchema#string